HC Wainwright & Co. assumes coverage of Insmed at Buy, sets price target at $220

What happened

HC Wainwright & Co. assumed coverage of Insmed with a Buy rating and set a $220 price target. The article says that target implies 110.6% upside from Insmed’s Nov. 3 closing price of $104.44. Recent analyst targets listed range from $201 to $220.

Confirmed

Global impact / market context

A new Buy rating and higher stated target can influence investor expectations, potentially supporting demand for Insmed shares. The target is an analyst estimate, not a guaranteed outcome; if investors treat it as achievable, they may position for gains, while disappointment could reverse that support.

Analyst inference

The article lists four recent analyst notes, with targets from $201 to $220, including Buy ratings from HC Wainwright and Guggenheim and an Overweight rating from Morgan Stanley. This provides evidence of generally positive published views, but does not establish future results or company performance.

Confirmed

What to watch

1. Watch whether Insmed’s share price moves toward or away from the $220 target; the article provides no subsequent trading data to show how investors responded. Analyst inference
2. Compare future analyst updates with the listed $201–$220 range, noting whether ratings or targets change and whether analysts explain the reasons for any revisions. Analyst inference
3. Look for company results or guidance that could support or weaken investor confidence in the expectations reflected by the $220 target; none are included here. Analyst inference

Evidence

• Original source link unavailable